Prescription drugs in Hungary are partly paid for by patients, and partly subsidised by the NEAK (the state health insurance body). The NEAK may recover part of its subsidies from manufacturers through agreed volume rebates, and the CJEU has previously ruled that manufacturers should adjust their output tax accordingly (Boehringer Case).
However, in the AG’s opinion it should still not be classified as a tax unless it was foreseeable by taxpayers that it was a tax. Novo Nordisk should treat the statutory payment in the same way as a volume rebate, and adjust its output tax.
Source: taxscape.deloitte.com
Note that this post was (partially) written with the help of AI. It is always useful to review the original source material, and where needed to obtain (local) advice from a specialist.
Latest Posts in "Hungary"
- Hungary’s NAV Launches Summer Inspection Campaign Targeting Key Sectors and Tax Violations
- Hungarian Tax Authority to Launch E-Receipt System for Real-Time Digital Receipts by 2026
- Hungary Modernizes E-Invoicing: B2G Mandate, Real-Time VAT Reporting, B2B Requirement by 2025
- NAV Online Invoice System 2025: Stricter Validation Rules Effective September 15, Impacting Businesses
- NAV Online Invoice System – stricter validations from September underscore NAV’s commitment to data quality
